Long
업데이트됨

ESPR a penny and medtech stock LONG

293
ESPR on the 120-minute chart is surging with momentum from an FDA approval for a new

cholestrol and lipid medication which will be an alternative to the at statin class which has

side effects and can cause diabetes. I am familar with a few of the professionals on the

science advisory board they are researchers and academics of the highest claiber. The chart

shows price testing and getting support from the mean VWAP and a little bit of resistance

from the first upper VWAP line. I have added to my existing position at the consolidation at

VWAP. I am well informed on ESPR market prospects; this could be disruptive.

The dual time frame RSI of Chris Moody has curled up and validates the idea. My interim

target is the double top of this past winter. I do expect increasing volume in time with the

price action that follows.

Disclaimer This a hot penny stock highly volatile - you could lose on this trade. Do not trade

with money you cannot afford to lose. You must manage the trade well to realize profit.

There are options if the put to call ratio is rising big money is pushing a reversal
노트
Nice action today. 25% of the position is closed.
액티브 트레이드
More volatility buying and selling zig zag fashion 스냅샷
액티브 트레이드
Price has ran up more than 20%- and is now in the upper VWAP bands and the upper
boundary of the Donchain channel. I am watching for an exit signal. The forecasting
algo suggests it is coming in the next few trading sessions. 스냅샷

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.